Key Highlights

  • Novocure’s Phase 3 TRIDENT trial missed its main survival goal.
  • Patients starting TTFields earlier lived a median 17.7 months.
  • Patients starting TTFields later lived a median 17.5 months.
  • The treatment remained safe, but the earlier start offered no clear overall benefit.

Novocure (NASDAQ:NVCR) announced results from the TRIDENT trial on June 18, 2026. The company wanted to answer a straightforward question: should patients with newly diagnosed glioblastoma begin Tumor Treating Fields therapy immediately alongside chemotherapy and radiation, or wait until the maintenance stage after chemoradiation is completed?

Tumor Treating Fields, known as TTFields, use low-intensity electric fields delivered through a wearable device. These fields are designed to disrupt the division of cancer cells.

The treatment is already used in glioblastoma. TRIDENT was intended to determine whether introducing it earlier could improve patient survival.

What Did the Trial Find?

The trial enrolled 981 patients and divided them into two groups.

The first group began TTFields therapy at the start of chemoradiation. The second group began the treatment later, during the maintenance phase.

Patients in the early-start group had a median overall survival of 17.7 months. Patients in the later-start group had a median survival of 17.5 months.

That difference of only 0.2 months, or roughly six days, was not statistically significant. This means the trial could not show that starting TTFields earlier genuinely improved survival.

The study therefore failed to meet its primary endpoint.

Why Does the Result Matter?

The result does not mean TTFields therapy has no value. Both groups received the treatment, and both recorded relatively durable survival outcomes.

Instead, the trial suggests that starting TTFields during chemoradiation may not be better than beginning it during the existing maintenance stage.

For Novocure, this limits the argument for expanding the therapy into an earlier part of the treatment process for all newly diagnosed glioblastoma patients.

It may also reduce the commercial opportunity linked specifically to earlier treatment use, because doctors and regulators generally require clear clinical evidence before changing standard treatment timing.

Were There Any Positive Findings?

The safety results were encouraging. Novocure reported no new safety concerns, and patients were able to use TTFields alongside chemotherapy and radiation.

Longer-term survival also showed some numerical differences. Three-year survival was 22.5% in the early-start group, compared with 18.4% in the maintenance-start group.

However, these figures do not change the main conclusion because the overall survival comparison was not statistically significant.

Novocure plans to present further analysis at the ASTRO 2026 Annual Meeting. That data may show whether certain patient groups benefited more than others.

What Happens Next?

Investors will now focus on whether the detailed trial results reveal useful subgroup findings. The company may examine factors such as age, tumour biology, surgical outcomes or treatment compliance.

However, subgroup analysis is usually considered less reliable when the main trial endpoint has failed.

The broader TTFields business remains intact, including its approved uses in several cancer indications. Even so, TRIDENT is a setback because it did not prove that earlier treatment improves survival across the wider glioblastoma population.